.jpg "Bio-Techne Corporation (NASDAQ: TECH)")
Today, the SVP – Novus Biologicals of Bio-Techne Corporation (NASDAQ: TECH), David Eansor, sold shares of TECH for $164.9K.
This is Eansor’s first transaction since reporting a Sell transaction on CBM back in January 2006
See today’s analyst top recommended stocks >>
Based on Bio-Techne Corporation’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $164 million and quarterly net profit of $19.72 million. In comparison, last year the company earned revenue of $144 million and had a net profit of $21.39 million. TECH’s market cap is $5.62B and the company has a P/E ratio of 49.96. Currently, Bio-Techne Corporation has an average volume of 111.3K.
The insider sentiment on Bio-Techne Corporation has been negative according to 24 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through three segments include: Biotechnology, Protein Platforms, and Diagnostics Divisions.
